Document:

Exhibit 10.25

 

 

Notice of Award

 

	 	RESEARCH

    Department of Health and Human Services

    National Institutes of Health

     

    NATIONAL INSTITUTE ON AGING
	Federal Award Date: 08/28/2020	 
	 	 	 	 

 

Grant
Number: 3R01AG058660-03S2

FAIN:
R01AG058660

 

Principal
Investigator(s):

SUSAN
M CATALANO, PHD

 

Project
Title: A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812
in Subjects with Mild to Moderate Alzheimer's Disease

 

Dr.
Susan Catalano

Cognition
Therapeutics, Inc.

2403
Sidney Street

Suite
261

Pittsburgh,
PA 15302

 

Award
e-mailed to: scatalano@cogrx.com

 

Period
Of Performance:

Budget
Period: 09/01/2020 - 05/31/2021

Project
Period: 09/15/2018 - 05/31/2021

 

Dear
Business Official:

 

The
National Institutes of Health hereby awards a grant in the amount of $278,623 (see “Award Calculation” in Section I and “Terms
and Conditions” in Section III) to COGNITION THERAPEUTICS, INC. in support of the above referenced project. This award is pursuant
to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated
or attached terms and conditions.

 

Acceptance
of this award including the “Terms and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise
obtained from the grant payment system.

 

Each
publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support
and a disclaimer such as “Research reported in this publication was supported by the National Institute On Aging of the National
Institutes of Health under Award Number R01AG058660. The content is solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of
this research, please notify the NIH awarding IC in advance to allow for coordination.

 

Award
recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct
and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest
(FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to
the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small
Business Technology Transfer (STTR) awards. Consult the NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the
regulation and additional important information.

 

    

     

    

 

If
you have any questions about this award, please contact the individual(s) referenced in Section IV.

 

Sincerely
yours,

 

Jessica
Perez

Grants
Management Officer

NATIONAL INSTITUTE ON AGING

 

Additional
information follows

 

    Page-2

     

    

 

SECTION
I - AWARD DATA - 3R01AG058660-03S2

 

Award Calculation (U.S. Dollars)

 

	Federal
                                            Direct Costs
 
	 	$	214,325	 
	Federal F&A Costs	 	$	64,298	 
	Approved Budget	 	$	278,623	 
	Total Amount of Federal Funds Obligated (Federal Share)	 	$	278,623	 
	TOTAL FEDERAL AWARD AMOUNT	 	$	278,623	 
	 	 	 	 	 
	AMOUNT OF THIS ACTION (FEDERAL SHARE)	 	$	278,623	 

 

	SUMMARY TOTAL FEDERAL AWARD AMOUNT YEAR ( 3 )	 
	GRANT NUMBER	 	 	TOTAL
                                            FEDERAL AWARD AMOUNT	 
	3R01AG058660-03S2	 	$	278,623	 
	5R01AG058660-03	 	$	5,774,586	 
	TOTAL	 	$	6,053,209	 

 

	SUMMARY TOTALS FOR ALL YEARS
	YR	 	 	 	THIS
                                            AWARD	 	 	 	CUMULATIVE
                                            TOTALS	 
	3	 	 	$	278,623	 	 	$	6,053,209	 

 

Fiscal Information:

	CFDA Name:	 	 	Aging
    Research	 
	CFDA Number:	 	 	93.866	 
	EIN:	 	 	1134365359A1	
	Document Number:	 	 	RAG058660A	 
	PMS Account Type:	 	 	P
                                            (Subaccount)	 
	Fiscal Year:	 	 	2020	 

 

	IC	 	 	CAN	 	 	2020	 
	AG	 	 	 	8033159	 	 	$	278,623	 

 

NIH Administrative Data:

PCC: 3CCCTLR / OC: 41023 / Released: PEREZJ 08/25/2020

Award Processed: 08/28/2020 12:18:20 AM

 

SECTION
II - PAYMENT/HOTLINE INFORMATION - 3R01AG058660-03S2

 

For payment
and HHS Office of Inspector General Hotline information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

 

SECTION
III - TERMS AND CONDITIONS - 3R01AG058660-03S2

 

This award
is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions
incorporated either directly or by reference in the following:

 

	 	a.	The grant program legislation and program regulation cited in this Notice of Award.
		b.	Conditions on activities and expenditure of funds in other statutory
                                            requirements, such as those included in appropriations acts.
	 	c.	45 CFR Part 75.
		d.	National Policy Requirements and all other requirements described in
                                            the NIH Grants Policy Statement, including addenda in effect as of the beginning date of
                                            the budget period.

		e.	Federal Award Performance Goals: As required by the periodic report in
                                            the RPPR or in the final progress report when applicable.
	 	f.	This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

 

(See NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm
for certain references cited above.)

 

    Page-3

     

    

 

Research and Development
(R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of “Research and
Development” at 45 CFR Part § 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on
the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V,
Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is
not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but
non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s)
specified in the award document(s).

 

An unobligated balance may be carried
over into the next budget period without Grants Management Officer prior approval.

 

This award is subject to the requirements
of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration
in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included.
See http://grants.nih.gov/grants/policy/awardconditions.htm for the full NIH award term implementing this requirement and other
additional information.

 

This award has been assigned the Federal
Award Identification Number (FAIN) R01AG058660. Recipients must document the assigned FAIN on each consortium/subaward issued under this
award.

 

Based on the project period start date
of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2
CFR Part 170. There are conditions that may exclude this award; see http://grants.nih.gov/grants/policy/awardconditions.htm for
additional award applicability information.

 

In accordance with P.L. 110-161, compliance
with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: http://publicaccess.nih.gov/.

 

This award represents the final year
of the competitive segment for this grant. See the NIH Grants Policy Statement Section 8.6 Closeout for complete closeout requirements
at: http://grants.nih.gov/grants/policy/policy.htm#gps.

 

A final expenditure Federal Financial
Report (FFR) (SF 425) must be submitted through the eRA Commons (Commons) within 120 days of the period of performance end date; see
the NIH Grants Policy Statement Section 8.6.1 Financial Reports, http://grants.nih.gov/grants/policy/policy.htm#gps, for additional
information on this submission requirement. The final FFR must indicate the exact balance of unobligated funds and may not reflect any
unliquidated obligations. There must be no discrepancies between the final FFR expenditure data and the Payment Management System's (PMS)
quarterly cash transaction data. A final quarterly federal cash transaction report is not required for awards in PMS B subaccounts (i.e.,
awards to foreign entities and to Federal agencies). NIH will close the awards using the last recorded cash drawdown level in PMS for
awards that do not require a final FFR on expenditures or quarterly federal cash transaction reporting. It is important to note that
for financial closeout, if a grantee fails to submit a required final expenditure FFR, NIH will close the grant using the last recorded
cash drawdown level. If the grantee submits a final expenditure FFR but does not reconcile any discrepancies between expenditures reported
on the final expenditure FFR and the last cash report to PMS, NIH will close the award at the lower amount. This could be considered
a debt or result in disallowed costs.

 

A Final Invention Statement and Certification
form (HHS 568), (not applicable to training, construction, conference or cancer education grants) must be submitted within 120 days of
the expiration date. The HHS 568 form may be downloaded at: http://grants.nih.gov/grants/forms.htm. This paragraph does not apply
to Training grants, Fellowships, and certain other programs—i.e., activity codes C06, D42, D43, D71, DP7, G07, G08, G11, K12, K16,
K30, P09, P40, P41, P51, R13, R25, R28, R30, R90, RL5, RL9, S10, S14, S15, U13, U14, U41, U42, U45, UC6, UC7, UR2, X01, X02.

 

    Page-4

     

    

 

Unless an application for competitive
renewal is submitted, a Final Research Performance Progress Report (Final RPPR) must also be submitted within 120 days of the period
of performance end date. If a competitive renewal application is submitted prior to that date, then an Interim RPPR must be submitted
by that date as well. Instructions for preparing an Interim or Final RPPR are at: https://grants.nih.gov/grants/rppr/rppr instruction
guide.pdf. Any other specific requirements set forth in the terms and conditions of the award must also be addressed in the Interim
or Final RPPR. Note that data reported within Section I of the Interim and Final RPPR forms will be made public and should be written
for a lay person audience.

 

NIH strongly encourages electronic
submission of the final invention statement through the Closeout feature in the Commons, but will accept an email or hard copy submission
as indicated below.

 

Email: The final invention statement
may be e-mailed as PDF attachments to: NIHCloseoutCenter@mail.nih.gov.

 

Hard copy: Paper submissions of the
final invention statement may be faxed to the NIH Division of Central Grants Processing, Grants Closeout Center, at 301-480-2304, or
mailed to:

 

National Institutes of Health

Office of Extramural Research Division
of Central Grants Processing

Grants Closeout Center 6705 Rockledge
Drive Suite 5016, MSC 7986

Bethesda, MD 20892-7986 (for regular
or U.S. Postal Service Express mail)

Bethesda, MD 20817 (for other courier/express
deliveries only)

 

NOTE: If this is the final year of
a competitive segment due to the transfer of the grant to another institution, then a Final RPPR is not required. However, a final expenditure
FFR is required and should be submitted electronically as noted above. If not already submitted, the Final Invention Statement is required
and should be sent directly to the assigned Grants Management Specialist.

 

In accordance with the regulatory requirements
provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements,
and procurement contracts with cumulative total value greater than $10,000,000 must report and maintain information in the System for
Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal
award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding
such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently
the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix
XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

 

Treatment of Program Income:

Additional Costs

 

SECTION
IV - AG Special Terms and Conditions - 3R01AG058660-03S2

 

Clinical Trial Indicator: No

This award does not support any NIH-defined
Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

 

Funding for this award has been provided
by Alzheimer's Disease Initiative funds.

 

Includes an administrative increase
of $278,623 in accordance with the e-Application submitted on 05/22/2020.

 

    Page-5

     

    

 

STAFF CONTACTS

 

The Grants Management Specialist is
responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and
provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals
work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should
be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

 

Grants Management Specialist:
Jennifer Edwards

Email: edwardsj@mail.nih.gov
Phone: 301-827-6689

 

Program Official: Laurie M.
Ryan

Email: ryanl@nia.nih.gov Phone:
301.496.9350 Fax: 301-496-1494

 

SPREADSHEET
SUMMARY

GRANT NUMBER: 3R01AG058660-03S2

INSTITUTION: COGNITION THERAPEUTICS, INC.

 

	Facilities and Administrative Costs	 	Year 3	 
	F&A Cost Rate 1	 	 	30	%
	F&A Cost Base 1	 	$	214,325	 
	F&A Costs 1	 	$	64,298	 

 

    Page-6Exhibit 10.26

 

Notice of Award

 

	
    
	Multi-Year Funded Research Project Grant	Federal Award Date: 09/05/2020	
    

	Department of Health and Human Services	 
	National Institutes of Health	 

 

NATIONAL INSTITUTE ON AGING 

 

	Grant Number:	1RF1AG051593-01
	FAIN:	RF1AG051593

 

Principal Investigator(s):

SUSAN M CATALANO, PHD

 

Project Title: Phase 1 safety trial for CT1812, a novel small
molecule therapeutic targeting a synaptic receptor for Abeta oligomers

 

Dr. Catalano, Susan

2403 Sidney Street

Suite 261

Pittsburgh, PA 152035118

 

Award e-mailed to: scatalano@cogrx.com

 

Period Of Performance:

Budget Period: 09/15/2016 - 06/30/2018

Project Period: 09/15/2016 - 06/30/2018

 

Dear Business Official:

 

The National Institutes of Health hereby awards a grant in the amount
of $2,410,669 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to COGNITION THERAPEUTICS,
INC. in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the
requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

 

Acceptance of this award including the “Terms and Conditions”
is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

 

Each publication, press release, or other document about research supported
by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication
was supported by the National Institute On Aging of the National Institutes of Health under Award Number RF1AG051593. The content is solely
the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior
to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

 

Award recipients must promote objectivity in research by establishing
standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free
from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation
at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation
does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the
NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional
important information.

 

    Page-1

     

    

 

If you have any questions about this award, please contact the individual(s)
referenced in Section IV.

 

Sincerely yours,

 

TRACI LAFFERTY

Grants Management Officer

NATIONAL INSTITUTE ON AGING

 

Additional information follows

 

    Page-2

     

    

 

SECTION I - AWARD DATA - 1RF1AG051593-01

 

	Award Calculation (U.S. Dollars)	 	 	 
	Salaries and Wages	 	$	200,532	 
	Personnel Costs (Subtotal)	 	$	200,532	 
	Other	 	$	1,728,003	 

 

	Federal Direct Costs	 	$	1,928,535	 
	Federal F&A Costs	 	$	482,134	 
	Approved Budget	 	$	2,410,669	 
	Total Amount of Federal Funds Obligated (Federal Share)	 	$	2,410,669	 
	TOTAL FEDERAL AWARD AMOUNT	 	$	2,410,669	 
	 	 	 	 	 
	AMOUNT OF THIS ACTION (FEDERAL SHARE)	 	$	2,410,669	 

 

SUMMARY TOTALS FOR ALL YEARS

	YR	 	 	THIS AWARD	 	 	 	CUMULATIVE TOTALS	 
	1	 	$	2,410,669	 	 	$	2,410,669	 

 

Fiscal Information:

	CFDA Name:	Aging Research
	CFDA Number:	93.866
	EIN:	1134365359A1
	Document Number:	RAG051593A
	PMS Account Type:	P (Subaccount)
	Fiscal Year:	2016

 

	IC	 	CAN	 	 	2016	 
	AG	 	 	8013663	 	 	$	2,410,669	 

 

NIH Administrative Data:

PCC: 3CCCTLR / OC: 414A / Released: LAFFERTYT 09/02/2016

Award Processed: 09/05/2016 12:01:24 AM

 

SECTION II - PAYMENT/HOTLINE INFORMATION
- 1RF1AG051593-01

 

For payment and HHS Office of Inspector General Hotline information,
see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

 

SECTION III - TERMS AND CONDITIONS
- 1RF1AG051593-01

 

This award is based on the application submitted to, and as approved
by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

 

		a.	The grant program legislation and program regulation cited in this Notice of Award.

 

		b.	Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.

 

    Page-3

     

    

 

		c.	45 CFR Part 75.

 

		d.	National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect
as of the beginning date of the budget period.

 

		e.	Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.

 

		f.	This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

 

(See NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm
for certain references cited above.)

 

Research and Development (R&D): All awards issued by the
National Institutes of Health (NIH) meet the definition of “Research and Development” at 45 CFR Part § 75.2. As
such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The
auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have
another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified
as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect
costs at a rate other than the rate(s) specified in the award document(s).

 

An unobligated balance may be carried over into the next budget period
without Grants Management Officer prior approval.

 

This grant is subject to Streamlined Noncompeting Award Procedures
(SNAP).

 

MULTI-YEAR FUNDED AWARD: This is a multi-year funded award.
A progress report is due annually on or before the anniversary of the budget/project period start date of the award, in accord with the
instructions posted at: http://grants.nih.gov/grants/policy/myf.htm.

 

This award is subject to the requirements of 2 CFR Part 25 for institutions
to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award
Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See http://grants.nih.gov/grants/policy/awardconditions.htm
for the full NIH award term implementing this requirement and other additional information.

 

This award has been assigned the Federal Award Identification Number
(FAIN) RF1AG051593. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

 

Based on the project period start date of this project, this award
is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions
that may exclude this award; see http://grants.nih.gov/grants/policy/awardconditions.htm for
additional award applicability information.

 

In accordance with P.L. 110-161, compliance with the NIH Public Access
Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: http://publicaccess.nih.gov/.

 

This award provides support for one or more clinical trials. By law
(Title VIII, Section 801 of Public Law 110-85), the “responsible party” must register
 “applicable clinical trials” on the ClinicalTrials.gov Protocol Registration System Information
Website. NIH encourages registration of all trials whether required under the law or not. For more information, see http://grants.nih.gov/ClinicalTrials
fdaaa/.

 

    Page-4

     

    

 

This award represents the final year of the competitive segment for
this grant. See the NIH Grants Policy Statement Section 8.6 Closeout for complete closeout requirements at: http://grants.nih.gov/grants/policy/policy.htm#gps.

 

A final expenditure Federal Financial Report (FFR) (SF 425) must be
submitted through the eRA Commons (Commons) within 120 days of the expiration date; see the NIH Grants Policy Statement Section 8.6.1
Financial Reports, http://grants.nih.gov/grants/policy/policy.htm#gps, for additional information
on this submission requirement. The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated
obligations. There must be no discrepancies between the final FFR expenditure data and the Payment Management System’s (PMS) quarterly
cash transaction data. A final quarterly federal cash transaction report is not required for awards in PMS B subaccounts (i.e., awards
to foreign entities and to Federal agencies). NIH will close the awards using the last recorded cash drawdown level in PMS for awards
that do not require a final FFR on expenditures or quarterly federal cash transaction reporting. It is important to note that for financial
closeout, if a grantee fails to submit a required final expenditure FFR, NIH will close the grant using the last recorded cash drawdown
level. If the grantee submits a final expenditure FFR but does not reconcile any discrepancies between expenditures reported on the final
expenditure FFR and the last cash report to PMS, NIH will close the award at the lower amount. This could be considered a debt or result
in disallowed costs.

 

A Final Invention Statement and Certification form (HHS 568), (not
applicable to training, construction, conference or cancer education grants) must be submitted within 120 days of the expiration date.
The HHS 568 form may be downloaded at: http://grants.nih.gov/grants/forms.htm. This paragraph
does not apply to Training grants, Fellowships, and certain other programs—i.e., activity codes C06, R13, R25, S10.

 

Unless an application for competitive renewal is submitted, a final
progress report must also be submitted within 120 days of the expiration date. Instructions for preparing a Final Progress Report are
at: http://grants.nih.gov/grants/funding/finalprogressreport.pdf. Any other specific requirements
set forth in the terms and conditions of the award must also be addressed in the final progress report. Institute/Centers may accept
the progress report contained in competitive renewal (type 2) in lieu of a separate final progress report. Contact the awarding IC for
IC- specific policy regarding acceptance of a progress report contained in a competitive renewal application in lieu of a separate final
progress report.

 

NIH strongly encourages electronic submission of the final progress
report and the final invention statement through the Closeout feature in the Commons, but will accept an email or hard copy submission
as indicated below.

 

Email: The final progress report and final invention statement may
be e-mailed as PDF attachments to: NIHCloseoutCenter@,mail.nih.gov.

 

Hard copy: Paper submissions of the final progress report and the final
invention statement may be faxed to the NIH Division of Central Grants Processing, Grants Closeout Center, at 301-4802304, or mailed
to:

 

National Institutes of Health

Office of Extramural Research

Division of Central Grants Processing

Grants Closeout Center

6705 Rockledge Drive

Suite 5016, MSC 7986

Bethesda, MD 20892-7986 (for regular or U.S. Postal Service Express mail)

Bethesda, MD 20817 (for other courier/express deliveries only)

 

NOTE: If this is the final year of a competitive segment due to the
transfer of the grant to another institution, then a Final Progress Report is not required. However, a final expenditure FFR is required
and should be submitted electronically as noted above. If not already submitted, the Final Invention Statement is required and should
be sent directly to the assigned Grants Management Specialist.

 

    Page-5

     

    

 

In accordance with the regulatory requirements provided at 45 CFR
75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement
contracts with cumulative total value greater than $10,000,000 must report and maintain information in the System for Award Management
(SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached
final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings.
Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee
Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR
Part 75. This term does not apply to NIH fellowships.

 

Treatment of Program Income:

Additional Costs

 

SECTION IV - AG Special Terms and
Conditions - 1RF1AG051593-01 Funding for this award has been provided by Alzheimer’s Disease Initiative funds.

 

RESTRICTION: This award includes $482,134 for Facilities and
Administration (F&A) costs. Of this amount, $482,134 is restricted pending the negotiation of an F&A rate(s). These restricted
funds may not be used for any purpose without the prior approval of the grants management official. If the rate(s) negotiated is(are)
lower than originally estimated/funded, this award amount may be revised downward.

 

The progress report for this multi-year funded (MYF) award is due
annually on or before the anniversary of the budget/project period start date of the award and must be submitted via the eRA Commons.
Additional information on submission requirements and directions can be found at http://grants.nih.gov/grants/policy/myf.htm.

 

None of the funds in this award shall be used to pay the salary of
an individual at a rate in excess of the current salary cap. Therefore, this award and/or future years are adjusted accordingly, if applicable.
Current salary cap levels can be found at the following URL: http://grants.nih.gov/grants/policy/salcap
summary.htm.

 

STAFF CONTACTS

 

The Grants Management Specialist is responsible for the negotiation,
award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official
is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project
administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the
Grants Management Specialist. Requests may be made via e-mail.

 

Grants Management Specialist: Robin Laney

Email: laneyr@nia.nih.gov Phone: 301-496-1472 Fax: 301-402-3672

 

Program Official: Laurie M. Ryan

Email: ryanl@nia.nih.gov Phone: 301.496.9350 Fax: 301-496-1494

 

SPREADSHEET SUMMARY

GRANT NUMBER: 1RF1AG051593-01

 

    Page-6

     

    

 

INSTITUTION: COGNITION THERAPEUTICS, INC.

 

	Budget	 	Year 1	 
	Salaries and Wages	 	$	200,532	 
	Personnel Costs (Subtotal)	 	$	200,532	 
	Other	 	$	1,728,003	 
	TOTAL FEDERAL DC	 	$	1,928,535	 
	TOTAL FEDERAL F&A	 	$	482,134	 
	TOTAL COST	 	$	2,410,669	 

 

	Facilities and Administrative Costs	 	Year 1	 
	F&A Cost Rate 1	 	 	25	%
	F&A Cost Base 1	 	$	1,928,535	 
	F&A Costs 1	 	$	482,134	 

 

    Page-7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]